feeds

2017

Please note: This is an ARCHIVED product. Use the Countries section of our website to find the most recent version (click here to access)

This report presents the top-level overview of the drug phenomenon in Luxembourg, covering drug supply, use and public health problems as well as drug policy and responses. The statistical data reported relate to 2015 (or most recent year) and are provided to the EMCDDA by the national focal point, unless stated otherwise 

2017

Please note: This is an ARCHIVED product. Use the Countries section of our website to find the most recent version (click here to access)

This report presents the top-level overview of the drug phenomenon in Denmark, covering drug supply, use and public health problems as well as drug policy and responses. The statistical data reported relate to 2015 (or most recent year) and are provided to the EMCDDA by the national focal point, unless stated otherwise.

2017

Please note: This is an ARCHIVED product. Use the Countries section of our website to find the most recent version (click here to access)

This report presents the top-level overview of the drug phenomenon in Cyprus, covering drug supply, use and public health problems as well as drug policy and responses. The statistical data reported relate to 2015 (or most recent year) and are provided to the EMCDDA by the national focal point, unless stated otherwise.

2017

Please note: This is an ARCHIVED product. Use the Countries section of our website to find the most recent version (click here to access)

This report presents the top-level overview of the drug phenomenon in Malta, covering drug supply, use and public health problems as well as drug policy and responses. The statistical data reported relate to 2015 (or most recent year) and are provided to the EMCDDA by the national focal point, unless stated otherwise. 

2017

Please note: This is an ARCHIVED product. Use the Countries section of our website to find the most recent version (click here to access)

This report presents the top-level overview of the drug phenomenon in the Netherlands, covering drug supply, use and public health problems as well as drug policy and responses. The statistical data reported relate to 2015 (or most recent year) and are provided to the EMCDDA by the national focal point, unless stated otherwise. 

2017

Please note: This is an ARCHIVED product. Use the Countries section of our website to find the most recent version (click here to access)

This report presents the top-level overview of the drug phenomenon in the Czech Republic, covering drug supply, use and public health problems as well as drug policy and responses. The statistical data reported relate to 2015 (or most recent year) and are provided to the EMCDDA by the national focal point, unless stated otherwise.

2017

Please note: This is an ARCHIVED product. Use the Countries section of our website to find the most recent version (click here to access)

This report presents the top-level overview of the drug phenomenon in Norway, covering drug supply, use and public health problems as well as drug policy and responses. The statistical data reported relate to 2015 (or most recent year) and are provided to the EMCDDA by the national focal point, unless stated otherwise 

2017

Please note: This is an ARCHIVED product. Use the Countries section of our website to find the most recent version (click here to access)

This report presents the top-level overview of the drug phenomenon in Poland, covering drug supply, use and public health problems as well as drug policy and responses. The statistical data reported relate to 2015 (or most recent year) and are provided to the EMCDDA by the national focal point, unless stated otherwise. 

2017

Please note: This is an ARCHIVED product. Use the Countries section of our website to find the most recent version (click here to access)

This report presents the top-level overview of the drug phenomenon in Portugal, covering drug supply, use and public health problems as well as drug policy and responses. The statistical data reported relate to 2015 (or most recent year) and are provided to the EMCDDA by the national focal point, unless stated otherwise. 

2017

Please note: This is an ARCHIVED product. Use the Countries section of our website to find the most recent version (click here to access)

This report presents the top-level overview of the drug phenomenon in Romania, covering drug supply, use and public health problems as well as drug policy and responses. The statistical data reported relate to 2015 (or most recent year) and are provided to the EMCDDA by the national focal point, unless stated otherwise. 

2017

Please note: This is an ARCHIVED product. Use the Countries section of our website to find the most recent version (click here to access)

This report presents the top-level overview of the drug phenomenon in Slovakia, covering drug supply, use and public health problems as well as drug policy and responses. The statistical data reported relate to 2015 (or most recent year) and are provided to the EMCDDA by the national focal point, unless stated otherwise. 

2017

Please note: This is an ARCHIVED product. Use the Countries section of our website to find the most recent version (click here to access)

This report presents the top-level overview of the drug phenomenon in Slovenia, covering drug supply, use and public health problems as well as drug policy and responses. The statistical data reported relate to 2015 (or most recent year) and are provided to the EMCDDA by the national focal point, unless stated otherwise. 

2017

Please note: This is an ARCHIVED product. Use the Countries section of our website to find the most recent version (click here to access)

This report presents the top-level overview of the drug phenomenon in Sweden, covering drug supply, use and public health problems as well as drug policy and responses. The statistical data reported relate to 2015 (or most recent year) and are provided to the EMCDDA by the national focal point, unless stated otherwise. 

2017

Please note: This is an ARCHIVED product. Use the Countries section of our website to find the most recent version (click here to access)

This report presents the top-level overview of the drug phenomenon in Bulgaria, covering drug supply, use and public health problems as well as drug policy and responses. The statistical data reported relate to 2015 (or most recent year) and are provided to the EMCDDA by the national focal point, unless stated otherwise. 

2017

Please note: This is an ARCHIVED product. Use the Countries section of our website to find the most recent version (click here to access)

This report presents the top-level overview of the drug phenomenon in Turkey, covering drug supply, use and public health problems as well as drug policy and responses. The statistical data reported relate to 2015 (or most recent year) and are provided to the EMCDDA by the national focal point, unless stated otherwise. 

2017

Please note: This is an ARCHIVED product. Use the Countries section of our website to find the most recent version (click here to access)

This report presents the top-level overview of the drug phenomenon in Austria, covering drug supply, use and public health problems as well as drug policy and responses. The statistical data reported relate to 2015 (or most recent year) and are provided to the EMCDDA by the national focal point, unless stated otherwise.

2017

The European market for hashish is currently one of the world’s largest and most profitable. About 647 tonnes of cannabis herb and 641 tonnes of hashish were consumed in the European Union in 2013 and the retail market has an overall value estimated conservatively to be about EUR 9.3 billion in 2013. This analysis describes how the supply of cannabis resin in Europe is changing in response to competition and other market developments.

Note that the online version contains additional interactive or audiovisual material not available in the PDF version.

2017

Synthetic cannabinoids represent the largest group of substances currently monitored in Europe by the EMCCDA through the EU Early Warning System. Current knowledge on these substances and trends in production, availability, use and harms are presented in this analysis.

2017

It is estimated that over 70 000 lives were lost to drug overdoses in Europe in the first decade of the twenty-first century. Reducing drug-related deaths therefore remains a major challenge for public health policy. This analysis describes some of the factors that increase the risk of fatal and non-fatal overdoses and a number of interventions developed to prevent these events.

06.06.2017
2017

Rising overdose deaths, the availability of new psychoactive substances and the growing health threat of potent synthetic opioids are among the issues highlighted in this year's European Drug Report.

2017

Please note: This is an ARCHIVED product. Use the Countries section of our website to find the most recent version (click here to access)

This report presents the top-level overview of the drug phenomenon in Latvia, covering drug supply, use and public health problems as well as drug policy and responses. The statistical data reported relate to 2015 (or most recent year) and are provided to the EMCDDA by the national focal point, unless stated otherwise. 

2017

This is the final version of the questionnaire on drug use among prisoners at European level. The questionnaire is the results of several years of work in the field of drugs and prison, which has included the agreement on a methodological framework or monitoring drug and prison in Europe, the analysis of existing questionnaires and a discussion among high level experts from several European countries and international organizations.

2017

Drug use can reduce the ability to drive a motor vehicle safely on the public road. European countries have developed various legal mechanisms to address this issue, using laws on road traffic or on drug control. This topic overview briefly describes the national laws in EU Member States and Norway, along with EU legislation, on drugs and driving.

10.05.2017
2017

The EMCDDA and the University Institute of Lisbon (ISCTE-IUL) will be strengthening their cooperation. 

11.04.2017
2017

Leading European and international experts are meeting in Lisbon this week for meetings around the theme of the internet, the exploitation of cyberspace and the transformational nature of new technologies.

04.04.2017
2017

The EMCDDA has published today its new Strategy 2025, which sets out an ambitious course of travel for the agency over the next decade.

2017

This strategy sets out an ambitious course of travel for the agency to 2025. It presents a vision to contribute to a healthier and more secure Europe, through better informed drug policy and action. Adopted unanimously by the agency’s key stakeholders in 2016, the strategy is the result of a year-long, in-depth analysis of the environment in which the EMCDDA operates. This analysis focused, in particular, on customer needs and a critical review of our internal capacity to meet them.

2017

This document gives an overview of the drug-related deaths (DRD) indicator, one of five key epidemiological indicators used by the EMCDDA for the collection and interpretaion of harmonised, good quality data at European level. It is written in an easy to understand manner and is intended for a wide readership.

31.03.2017
2017

What do the latest data tell us about the European drug market? What are the new trends in drug use among European adults and school students?

2017

This report provides an overview of the various types of brief interventions (BIs) currently used in European countries in the field of substance use, particularly illicit drugs. Targeted at policymakers and practitioners alike, it covers more than 30 BIs carried out in the EU and serves as a starting point for preparing concrete proposals to improve the evidence base on this topic.

Loading